Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease
- Cite this article as:
- Batzloff, M.R., Pandey, M., Olive, C. et al. Immunol Res (2006) 35: 233. doi:10.1385/IR:35:3:233
Rheumatic fever (RF) and rheumatic heart disease (RHD) are post-infectious complications of an infection (or repeated infection) with the Gram-positive bacterium Streptococcus pyogenes (also known as group A streptococcus, GAS). RF and RHD are global problems and affect many indigenous populations of developed countries and many developing countries. However, RF and RHD are only part of a larger spectrum of diseases caused by this organism. The development of a vaccine against GAS has primarily targeted the abundant cell-surface protein called the M-protein. This review focuses on different M-protein-based-subunit vaccine approaches and the different delivery technologies used to administer these vaccine candidates in preclinical studies.